Aura BioSciences banks $4.5M from private backers

Cambridge, MA-based Aura BioSciences says it has rounded up $4.5 million from unnamed investors to back its work on an innovative nanotech delivery system for cancer drugs. As Xconomy notes, Aura is working with nanoparticles engineered to resemble a virus. "We retain the intelligence of the virus particles so they only target tumors," CEO Elizabeth de los Pinos, an Eli Lilly veteran, tells the tech news service. "Because they are empty shells, they never replicate. We further modified them so the immune system won't trap them." Story

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.